Connor, Clark & Lunn Investment Management Ltd. Veracyte, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Veracyte, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 22,650 shares of VCYT stock, worth $481,539. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,650
Previous 12,629
79.35%
Holding current value
$481,539
Previous $347,000
44.38%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding VCYT
# of Institutions
257Shares Held
81.7MCall Options Held
43KPut Options Held
82K-
Vanguard Group Inc Valley Forge, PA7.38MShares$157 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA7.37MShares$157 Million0.03% of portfolio
-
Black Rock Inc. New York, NY7.21MShares$153 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.04MShares$150 Million1.11% of portfolio
-
State Street Corp Boston, MA4.33MShares$92 Million0.0% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $1.52B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...